Inpharma 1425 - 21 Feb 2004

■ The nucleoside reverse transcriptase inhibitorDPC 817* markedly reduced HIV viral load in aphase II trial that was presented at the 11thConference on Retroviruses and OpportunisticInfections held in San Francisco, US. A total of30 treatment-naive patients with plasma HIV-1 RNAlevels of > 5000 copies/mL and CD4+ cell counts of> 50 cells/mm3 were randomised to receive DPC 817[Reverset] 50, 100, or 200 mg/day, or placebo, for10 days. Viral load was reduced by a mean of 1.67,1.74 and 1.77 log10 by the 50, 100, and 200 mg/daydosages of DPC 817, respectively. The incidences ofadverse events were comparable between the activeand placebo groups.* Pharmasset; phase II for HIV infections

Pharmasset Inc. Pharmasset Reports Phase 2 HIV Study Results ofReverset(TM): Once-Daily Oral Dose Reduced HIV Viral Load by 1.77Log(10) copies/mL. Media Release : 11 Feb 2004. Available from: URL: http://www.pharmasset.com 809031185

1

Inpharma 21 Feb 2004 No. 14251173-8324/10/1425-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved